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Annual risk of ONJ was the least important attribute. ConClusions: When making 
treatment decisions regarding choice of BTA for patients with bone metastases, the 
main treatment goals for Turkish physicians are reducing risk of renal impairment 
and delaying first SRE.
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objeCtives: To assess EQ-5D-5L validity in patients with acute stroke, in com-
parison to EQ-5D-3L, EQ VAS, modified Rankin Scale (mRS) and Barthel Index 
(BI). Methods: Cross-sectional study of 408 patients (51.5% males; mean age 69 
years), after median 8 days from stroke onset. We assessed: construct validity in 
terms of known-groups validity, convergent validity of EQ-5D-5L dimensions with 
other stroke outcome measures, and criterion-related validity in terms of concur-
rent validity, with mRS as a gold standard. Results: A total of 2.9% EQ-5D-5L and 
3.7% EQ-5D-3L questionnaires had at least one missing answer, indicating good 
feasibility of both instruments in patients with stroke. The proportion of patients 
reporting ‘no problems’ was 38.2% for BI, 6.1% for EQ-5D-3L, 5.6% for EQ-5D-5L, 
5.0% for mRS and 2.5% for EQ VAS. Results of the known-groups validity tests con-
firmed prior hypotheses: health state utilities were lower in females, patients with 
high mRS score, low BI or VAS score, patients with subarachnoid hemorrhage or 
intracerebral hemorrhage, and when proxy respondent was used. Convergence of 
EQ-5D-5L dimensions with mRS, BI and EQ VAS was improved or at least the same 
as EQ-5D-3L dimensions. For predicting outcome in patients with stroke, the sum 
of mRS related EQ-5D-5L dimensions (Mobility, Self-care, Usual activities), gave 1% 
of false positive and 0% of false negative results. ConClusions: Results support 
the validity of the EQ-5D-5L descriptive system as a generic measure assessed by 
self-report and proxy in patients with acute stroke, demonstrating some psycho-
metric advantages in comparison to EQ-5D-3L and substantially lower ceiling effect 
in comparison to Barthel Index.
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objeCtives: EQ-5D has been widely used to measure health status in a variety of 
conditions and the amount of evidence of its performance has increased over recent 
years. The aim of this study was to consolidate this evidence by reviewing papers 
reporting systematic reviews of the psychometric properties (validity and reliability) 
and/or responsiveness of EQ-5D. Methods: Medline and Embase were searched 
for systematic reviews of the performance of EQ-5D. Supplementary searches were 
carried out in Cochrane Library, Web of Science, reference lists of included studies, 
the EuroQol database and hand searching of EuroQol Scientific Plenary Proceedings. 
In addition the website of the Oxford Patient Reported Outcome Measures (PROMs) 
Group was searched for reports. Data were extracted using a template designed 
specifically for the study. Results: 25 reviews were identified in this study and a 
further 18 were identified from the Oxford PROMs group website. The majority of 
studies focussed on adults. Overall there was evidence of good to fair performance 
of EQ-5D in depression, diabetes (type 2), rheumatoid arthritis, skin conditions, can-
cer, cardiovascular disease, asthma, personality disorder and urinary incontinence. 
Evidence was mixed in COPD, dementia, schizophrenia and vision disorders, and 
poor for hearing disorders. The was little evidence for liver transplantation, venous 
leg ulcers, haemophilia, bipolar disorder and low back pain; although limited, the 
evidence showed positive results for liver transplantation, haemophilia and leg 
ulcers. No evidence was identified for, among others, skin cancer and systemic lupus 
erythematous. ConClusions: This study has provided a comprehensive overview 
of the evidence of the performance of EQ-5D. Most evidence suggests good psycho-
metric properties of EQ-5D; however there are particular concerns about its ability 
to capture the impact of dementia, schizophrenia, visual impairment and hearing 
disorders. Further research is encouraged in conditions where data or reviews of 
psychometric properties of EQ-5D are lacking.
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objeCtives: To investigate health-related quality of life (HRQoL) in Italian 
patients with moderate and severe Crohn’s disease (CD) (Harvey Bradshaw 
Index> 8). Methods: EuroQoL 5-dimension 3-level (EQ-5D-3L) questionnaire 
and visual analogue scale (VAS) were administered to 540 consecutive patients 
with moderate and severe CD who referred to a convenience sample of 38 Italian 
inflammatory bowel disease centres (21 teaching-hospitals; 4 research hospitals; 
8 self-governing hospitals; 3 Local Health Authority hospitals; 2 private hospi-
tals) participating in the ongoing Survey on Quality Of Life in Crohn’s Patients (SOLE) 
objeCtives: Currently no measure can identify, with a high degree of positive pre-
dictive power, suicidal behavior. Because suicide occurs at a low base-rate, studies 
of instruments designed to predict this outcome often lack an adequate sample 
size to prove the tool’s predictive ability. Our aim is to identify an assessment with 
the most promise of predicting suicidal behavior in veteran or military patients and 
present options to overcome previous research hurdles. Methods: Two systematic 
reviews, one performed for the US Department of Veterans [1], and the other as 
part of NICE guidance development [2] provided the background for our analy-
sis. These summaries were reviewed to identify the most predictive assessments 
yet developed. Sensitivity, specificity, positive and negative predictive power were 
tabulated for all reported instruments. Study limitations were recorded along with 
these results. Results: One instrument showed promise of meeting the objec-
tive. The Affective States Questionnaire (ASQ) was able to predict suicide within 3 
months with a sensitivity of 60%, specificity of 74% and positive predictive power 
of 32% [3]. The study that produced those results was performed on an inpatient 
and outpatient veteran population. However, the sample was small with only 283 
patients and the risk of bias was unclear. A larger study may provide the needed 
evidence to make the Affective States Questionnaire a useful screening tool. We 
propose the Affective States Questionnaire be transferred to electronic administra-
tion and provided as part of routine admissions at VA facilities. Deploying the tool 
electronically could provide the large sample sizes required to detect effects on this 
low base-rate outcome. ConClusions: The Affective States Questionnaire shows 
promise of becoming an appropriate screening tool for suicide in a military popu-
lation. Electronic capture may allow for large scale deployment, therefore gaining 
sufficient sample to determine applicability as a screening tool.
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objeCtives: To evaluate psychometric properties of the revised Self-Injection 
Assessment Questionnaire in rheumatoid arthritis patients (pts) receiving certoli-
zumab pegol. Methods: In the study (NCT00674362), pts with low to moderate 
rheumatoid arthritis (RA) received certolizumab pegol (CZP; 400mg at Weeks [Wks] 
0, 2, 4, then 200mg every other wk). In the open-label extension (OLE; NCT00843778), 
pts could self-administer CZP using a pre-filled syringe. Pts in OLE completed the 
revised Self-Injection Assessment Questionnaire (SIAQv2.0
©) at Wks 0, 2, 4, 6, 8, 10, 12. 
Domain scores were calculated per authors’ recommendations, and internal consist-
ency was assessed using the Cronbach’s alpha statistics. Floor and ceiling effects 
were reported as % pts with the worst/best domain score. Construct validity was 
assessed by confirmatory factor analysis fitting the current conceptual framework 
of the questionnaire and by calculating the Bentler’s Comparative Fit Index (CFI) 
and the root mean square error of approximation (RMSEA). Results: 86 pts (mean 
age: 50.8 years; disease duration: 4.6 years) entered the OLE and completed the SIAQ 
at least once. At first self-injection visit, DAS28 (ESR) was 4.0 and HAQ-DI 0.9. The 
internal consistency of all domains was > 0.8 at any visit. Floor effect was < 5% at any 
visit; ceiling effect was ≤ 13% for Self-Confidence, Ease of Use (EU) and Satisfaction 
domains, but reached 40% for Feeling and Injection-Site Reactions domains. The 
ceiling effect of the EU domain was lower (10%) than the original validation (22%). 
The conceptual framework structure was supported by the confirmatory factor 
analysis with CFI values of 0.75–0.86 and RMSEA values of 0.10–0.13, which, given 
the limited sample size, would indicate reasonable goodness of fit. ConClusions: 
Modifications brought to the SIAQv2.0
© appeared to remediate the acquiescence 
bias issue that was noted during the validation of SIAQv1. The appropriateness 
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objeCtives: To evaluate Turkish physicians’ preferences when selecting 
between the different bone-targeted agents (BTAs) available for preventing skel-
etal-related events (SREs) in patients with bone metastases from advanced solid 
tumors. Methods: Physicians from several centres, currently treating patients with 
bone metastases from solid tumours were recruited by phone or personal invitation 
and then engaged in a face-to-face interview where they completed a web-ena-
bled discrete-choice experiment survey. Each survey included 10 choices between 
pairs of hypothetical treatment profiles for the two putative patient profiles. The 
hypothetical treatment profiles included five attributes within a pre-defined range 
(based on prescribing information): time until first SRE (10, 18 and 28 months); time 
until worsening of pain (3, 6 and 10 months); annual risk of osteonecrosis of the 
jaw (ONJ; 0, 1 and 5%); annual risk of renal impairment (0,4 and 10%); and mode 
of administration (oral tablet, subcutaneous injection, 15-minute or 120-minute 
intravenous infusion). Choice questions were based on an experimental design 
with known statistical properties. A main-effects random parameters logit model 
was estimated. Results: A total of 105 physicians agreed to participate in the 
face-to-face interview and accessed the online survey. Of these, 104 physicians 
were eligible and consented to participate and 99 were included in the analysis. 
Estimated preference weights for all applicable attributes were consistent with the 
natural ordering of the categories. Risk of renal impairment and months until first 
SRE were the most important attributes influencing physicians’ decisions, with 
better clinical outcomes preferred to worse outcomes. Preventing pain progres-
sion was the third most important attribute followed by mode of administration. 
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mood or affective states: 1) Tension-Anxiety, 2) Vigour-Activity, 3) Depression-
Dejection, 4) Fatigue-Inertia, 5) Anger-Hostility, and 6) Confusion-Bewilderment. 
“Lively” (item 7) and “full of pep” (item 56) belong to the Vigor-Activity domain. 
The objectives of this study were to evaluate the difference in concept 
(if any) between these items and to translate them in 7 languages (Bulgarian, 
Estonian, French, German, Latvian, Portuguese and Slovakian). Methods: The 
POMS was translated following the Mapi methodology in compliance with the 
ISPOR guidelines. The process consisted of: 1) definition of each concept behind 
each item, 2) two forward translations by native translators, reconciliation of the 
translations, 3) one back-translation by an English-speaker fluent in the target lan-
guage, 4) final reconciliation, and 5) cognitive interviews with 35 native-speaking 
healthy subjects (n= 5 per country). Results: The first step of the translation 
process, i.e., definition of concepts, helped to clarify the conceptual differences 
between “lively” and “full of pep”. “Lively” had to be considered more as an action 
or behavior-based descriptor and “full of pep” as descriptive of the internal state. 
“Lively” was considered as the manifestation of feeling “full of pep”: With this 
definition in mind, each local team could find appropriate equivalents in each 
language. “Lively” was translated with literal wording in all languages. As for “full 
of pep”, translations varied from “enthusiastic” (Bulgarian, Portuguese) to “full of 
vitality” (Estonian, Slovakian) or “peppy” (German), “full of spirit” in French and 
“full of energy “in Latvian. The translations were well understood. ConClusions: 
“Lively” and “full of pep” are two different concepts which could be easily trans-
lated with the help of the developers who provided clear definitions of the intent 
of each item.
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objeCtives: The collection of patient-reported outcome (PRO) data is becoming 
more routine in oncology clinical trials and in clinical practice. The European 
Organisation for Research and Treatment of Cancer (EORTC) has developed and 
validated a number of PRO instruments, including the QLQ-BR23, a breast cancer 
specific measure. The objective of this study was to evaluate the internal reli-
ability of the EORTC QLQ-BR23 through reliability generalisation, a meta-analytic 
technique for pooling Cronbach’s alpha coefficients. Methods: A systematic lit-
erature review was undertaken of articles reporting the internal reliability of the 
EORTC QLQ-BR23 to identify potential studies for inclusion. Internal reliability was 
assessed for each of the five domains of the EORTC QLQ-BR23: Body (BI), Sexual 
Functioning (SF), Arm Symptoms (AS), Breast Symptoms (BS) and Systemic Therapy 
Side Effects (ST). Reliability generalisation was undertaken using fixed and random 
effects models for each domain. A value for Cronbach’s alpha coefficient above 
0.70 was considered to indicate reliability. Results: A total of 15 studies were 
found resulting in 18 datasets. Of the 3102 patients who had been recruited into 
studies 2888 had completed the BR-23 (93%). Almost half the studies had used 
European language versions of the instrument (7/15,47%). The unweighted average 
(fixed effects) Cronbach’s alpha coefficient ranged from 0.69 (breast symptoms) to 
0.86 (sexual functioning). There was statistically significant heterogeneity present 
across the 5 domains under the fixed effects model justifying the use of random 
effects. All Cronbach’s alpha > 0.7 under the random effects model, e.g. BI: 0.84 
(95%CI: 0.80-0.87), SF: 0.87 (95%CI: 0.84-0.89), AS: 0.71 (95%CI: 0.66-0.76), BS: 0.70 
(95%CI: 0.65-0.74) and ST: 0.71 (95%CI: 0.66-0.75). ConClusions: The results sug-
gest that the 5 domains of the EORTC QLQ-B23 are reliable and may be used in 
clinical trials and practice to capture PRO data to help inform trial, as well as 
individual clinical decision-making processes.
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objeCtives: Empirical data suggest that compliance with diabetes clinical prac-
tice recommendations is inadequate in primary care and that a large proportion of 
patients with diabetes remain at high risk. Changing physician practice patterns 
with use of electronic integrated system would provide a suite of technologies to 
support a full range of diabetes management activities. The objectives of this study 
are to determine the financial and clinical benefits of implementing information 
technology enabled diabetes management systems. Methods: The simulations 
were performed using the CORE model – widely validated and broadly used to 
enable a reliable estimation of costs and clinical effects associated with diabetes. 
Several estimates of care process improvements were derived, representing dif-
ferent percentage of patients covered by designed management activities and 
reaching target HbA1c. The primary outcome was medical cost savings and sec-
ondary measures include reduction of cardiovascular, cerebrovascular, neuropathy, 
nephropathy, and retinopathy clinical outcomes. Results: Gradual, sustained, 
and statistically significant improvements in a lifelong perspective performance 
measures were observed. According to simulation, as percentage of patients cov-
ered by information technology enabled diabetes management is growing, health 
care expenditures are reduced. With 10% of patients covered 6% of total patient 
costs were saved in comparison to 23% of total patient costs saved with 100% 
of patients covered. ConClusions: Implementation of information technology 
enabled diabetes management has demonstrated significant potential for improv-
ing processes of care, preventing the development of diabetic complications, and 
generating cost savings. Moreover, this improves the synthesis of information, 
the delivery of knowledge, and the efficiency of communication, allowing for 
coordination of care across delivery teams.
during 2012. As Italian EQ-5D-3L tariffs were not available at the time of the research, 
UK ones were used according to other comparable studies. Results concerning the 
first out of the 4 visits planned in SOLE study were reported as mean, standard 
deviation (SD), median and range. Correlation between EQ-5D-3L questionnaire and 
VAS scores was investigated via Kendall’s tau-b (Ktau-b). Results: 531 patients 
(mean age: 41.3; SD: 13.8; median: 41; range: 18—84) responded to EQ-5D-3L ques-
tionnaire (98.3%) and 536 to VAS (99.6%). The most frequently marked levels for 
EQ-5D-3L questionnaire were: 1 for mobility (66.2%) and self-care (85.2%); 2 for 
usual activities (51.8%), pain/discomfort (70.7%), and anxiety/depression (53.4%). 
Overall scores for EQ-5D-3L questionnaire and VAS were 0.7 (SD: 0.3; median: 0.8; 
range: -0.2—1) and 54.3 (SD: 20.8; median: 55; range: 0—100), respectively. Six out of 
531 EQ-5D-3L questionnaire responders (1.1%) valued their health state potentially 
worse than death (utility< 0). VAS scores of 10 or multiple of 10 were marked by 298 
out of 536 patients (55.6%). Ktau-b between EQ-5D-3L questionnaire and VAS scores 
reached 0.45 (p< 0.001). No significant differences were detected when EQ-5D-3L 
questionnaire and VAS scores were stratified according to hospital institutional 
features. ConClusions: Italian patients with moderate and severe CD report a 
remarkable reduction in HRQoL.
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objeCtives: Sample size (N) affects the robustness of psychometric results, but for 
evaluations of patient-reported outcome (PRO) measures, N is often a compromise 
between timelines and resources. Currently, there are no psychometric N guide-
lines or requirements for the development of PROs for use in clinical trials. The 
objective of this study is to review current N practices by conducting a systematic 
literature review of the psychometric methods and N choices made in the evaluation 
of PRO measures (for use in clinical trials) over the past 10 years. Methods: This 
systematic literature review included abstracts that described the psychometric 
evaluation of PRO measures that were likely developed for use in clinical trials. The 
review included English-language journal abstracts published in the past 10 years 
and identified in PubMed. Characteristics of each study were tabulated including 
the number of items and dimensions in each PRO of interest, the psychometric 
methods employed (e.g., internal consistency, test-retest reliability, factor analy-
sis, responsiveness), and N. Results: The literature search yielded 252 abstracts 
describing studies conducted mostly in Europe, Canada, and the United States. 
Preliminary results indicate that Ns ranged from approximately 40 to 4,000. The 
most frequently reported psychometric method was Cronbach’s alpha to quantify 
internal consistency. Approximately thirty percent of studies employed methods 
that demand the largest Ns such as item response theory (IRT) and factor analysis 
(FA). Ns for studies using IRT or FA analysis ranged from approximately 100 to 4,000 
participants. ConClusions: A wide range of Ns were employed for the psychomet-
ric evaluation of PROs developed for use in clinical trials. Ideally, researchers should 
consider the complexity of the PRO measure, its intended use, and the purpose of 
the evaluation when deciding on a study N. Additional studies should work toward 
developing best practices for PRO N guidelines in clinical trials.
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objeCtives: The EuroQol group observed problems related to the quality of valu-
ation data collected using the 5L protocol. The objective of this study was to test if 
reintroducing a ranking task prior to TTO could help to improve the quality of the 
data. Methods: Respondents were assigned to three different study branches in 
Spain, while just two branches were used in Japan. The control group (Arm 1, both 
countries) was the 5L protocol. The second branch (Arm 2, just Spain) was the EQ-VT 
preceded by a ranking task, in which the respondents were asked to rank the target 
health states using physical cards. The last branch (Arm 3, both countries) was 
with ranking prior to the EQ-VT, but unlike the second branch, the ranked states 
remained visible through the Composite TTO (C-TTO) tasks, and the C-TTO states 
order were determined by the rank order. A sample of respondents was randomly 
selected from Canary Islands and Tokyo population. All interviews were performed 
face to face. We compared the number of C-TTO-based inconsistencies. Results: 
The final sample size was 932 respondents (141 and 191 for branches 1 and 3 respec-
tively in Japan and 196,205 and 199 for branches 1, 2 and 3 respectively in Spain). 
The percentages of inconsistencies on C-TTO responses (state 55555 not valued as 
the worst state) were 13.27%, 10.73% and 13.57% for branches 1, 2, 3 respectively in 
Spain, and 20.6% and 10.5% for branches 1 and 3 in Japan. Grouping the data, the 
inconsistencies were 16.3%; 10.7% and 12.1%. However, none of the observed dif-
ferences were statistically significant. ConClusions: Differences in proportions 
observed in the Spanish data are smaller than in Japanese data. Given that Japanese 
team did all control arm interviews prior to ranking task interviews could play in 
favor of ranking arm (learning effects).
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objeCtives: Feeling “lively” or “full of pep” are common items used in PRO meas-
ures. The Profile of Mood States (POMS) identifies and assesses six fluctuating 
